These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9927120)

  • 1. Recombinant human erythropoietin and blood management in pediatric spine surgery.
    Roye DP
    Orthopedics; 1999 Jan; 22(1 Suppl):s158-60. PubMed ID: 9927120
    [No Abstract]   [Full Text] [Related]  

  • 2. Blood loss and transfusion management in spinal surgery.
    Dekutoski MB
    Orthopedics; 1999 Jan; 22(1 Suppl):s155-7. PubMed ID: 9927119
    [No Abstract]   [Full Text] [Related]  

  • 3. Erythropoietic therapy: cost efficiency and reimbursement.
    Jaspan D
    Am J Health Syst Pharm; 2007 Aug; 64(16 Suppl 11):S19-29. PubMed ID: 17687067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Questionable conclusions about epoetin alfa.
    Kruse MW; Lee JJ
    Am J Health Syst Pharm; 2007 Sep; 64(17):1789-90; author reply 1790-1. PubMed ID: 17724355
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.
    Martin SC; Gagnon DD; Zhang L; Bokemeyer C; Van Marwijk Kooy M; van Hout B
    Pharmacoeconomics; 2003; 21(16):1153-69. PubMed ID: 14594437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Lefebvre P; Vekeman F; Cremieux PY
    Ann Pharmacother; 2010 Mar; 44(3):595; author reply 595-6. PubMed ID: 20179253
    [No Abstract]   [Full Text] [Related]  

  • 7. [Preoperative strategy for homologous blood salvage and peri-operative erythropoietin].
    Rosencher N; Woimant G; Ozier Y; Conseiller C
    Transfus Clin Biol; 1999 Dec; 6(6):370-9. PubMed ID: 10666795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis.
    Ortega A; Dranitsaris G; Puodziunas AL
    Cancer; 1998 Dec; 83(12):2588-96. PubMed ID: 9874467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-dose epoetin alfa reduces blood transfusions compared with autologous donation.
    Hardwick ME; Morris BM; Colwell CW
    Clin Orthop Relat Res; 2004 Jun; (423):240-4. PubMed ID: 15232456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimizing transfusion requirements for children undergoing craniosynostosis repair: the CHoR protocol.
    Vega RA; Lyon C; Kierce JF; Tye GW; Ritter AM; Rhodes JL
    J Neurosurg Pediatr; 2014 Aug; 14(2):190-5. PubMed ID: 24877603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, randomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty.
    Stowell CP; Chandler H; Jové M; Guilfoyle M; Wacholtz MC
    Orthopedics; 1999 Jan; 22(1 Suppl):s105-12. PubMed ID: 9927110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood management challenges in revision hip arthroplasty.
    Longjohn DB; Dorr LD; McPherson EJ
    Orthopedics; 1999 Jan; 22(1 Suppl):s148-50. PubMed ID: 9927117
    [No Abstract]   [Full Text] [Related]  

  • 14. Erythropoietic agents for anemia of critical illness.
    Shermock KM; Horn E; Rice TL
    Am J Health Syst Pharm; 2008 Mar; 65(6):540-6. PubMed ID: 18319499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of Epoetin alfa in complex spine deformity surgery.
    Shapiro GS; Boachie-Adjei O; Dhawlikar SH; Maier LS
    Spine (Phila Pa 1976); 2002 Sep; 27(18):2067-71. PubMed ID: 12634571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful blood conservation during craniosynostotic correction with dual therapy using procrit and cell saver.
    Krajewski K; Ashley RK; Pung N; Wald S; Lazareff J; Kawamoto HK; Bradley JP
    J Craniofac Surg; 2008 Jan; 19(1):101-5. PubMed ID: 18216672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.
    Driver PS
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S12-6. PubMed ID: 9872688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood conservation in the critically ill.
    Thomas J; Martinez A
    Am J Health Syst Pharm; 2007 Aug; 64(16 Suppl 11):S11-8. PubMed ID: 17687066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proceedings of the roundtable of experts in surgery blood management. Vienna, Austria, April 7-9, 1995.
    Semin Hematol; 1996 Apr; 33(2 Suppl 2):1-80. PubMed ID: 8999552
    [No Abstract]   [Full Text] [Related]  

  • 20. Switching from i.v. to s.c. epoetin in hemodialysis patients.
    Knauss MD; Walton T; Macon EJ
    Am J Health Syst Pharm; 2002 Sep; 59(18):1783-4. PubMed ID: 12298119
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.